A pilot study for comparative clinical trial on the therapeutic effect of tacrolimus (Prograf cap®) in adult patient with minimal change nephritic syndrome.

Eligibility

Ages Eligible for Study:

18 Years to 80 Years (Adult, Senior)

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

No

Criteria

Inclusion Criteria:

from 18yrs to 80 yrs , man and women

Minimal change disease is diagnosed by kidney biopsy

On screening, the patient shows that the level of urine protein/creatinine ratio is over 3.0

On screening, the patient shows that the serum albumin is below 3.0g/dL

the patient sign on the concent form

Exclusion Criteria:

the patient have experience to take tacrolimus or cyclosporin for 1 month

If it is the relapse of the nephrotic syndrome, before relapse, the maintenance dose of steroid is over 0.3 mg/kg/day

steroid dependent or steroid resistant or frequent relapse case

uncontrolled hypertension

pregnancy or anticipate pregnancy with 6 month

hypersensitivity to tacrolimus or macrolide

acute hepatitis or the level of AST or ALT is over 2 times of normal range or the level of bilirubin is over 2.0 mg/dL

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01084980